Cenerimod is primarily investigated for its potential therapeutic applications in autoimmune diseases, particularly multiple sclerosis (MS). It functions as a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, which helps in regulating the immune response by preventing the egress of lymphocytes from lymph nodes. This mechanism reduces the migration of autoreactive immune cells to the central nervous system, thereby mitigating inflammation and damage associated with MS. Clinical trials have explored its efficacy and safety in managing relapsing forms of MS, with promising results in reducing relapse rates and slowing disease progression. Additionally, its immunomodulatory properties are being studied for potential use in other autoimmune conditions, such as systemic lupus erythematosus (SLE), where it may help in controlling overactive immune responses. Ongoing research continues to evaluate its broader applications in autoimmune and inflammatory disorders.